Introduction
============

Epilepsy is common among people of any age, region and race. There are various manifestations of epilepsy, and status epilepticus (SE) can occur in all kinds of epilepsy. Apoptosis is a major way of neuron loss after SE ([@b1-etm-0-0-6250]). Some studies have confirmed that epileptic seizures could cause damage of hippocampal neurons, and this damage might be one of the most important factors in the reconstruction of loop during recurrent seizures ([@b2-etm-0-0-6250]). The phosphatidyl inositol 3-kinase (PI3K)/Akt pathway may be an important signal transduction pathway for epileptic seizures. Bcl-2 and Bad belong to anti-apoptotic and pro-apoptotic proteins respectively, which play important roles in the mitochondrial apoptosis pathway. Recent studies have found that erythropoietin (Epo) is not merely a hematopoietic factor in a conventional way, but rather an important factor with multiple functions. The results of many animal models with nervous system damage have shown that Epo may reduce brain damage and improve nervous system function by reducing apoptosis and promoting survival ([@b3-etm-0-0-6250]--[@b7-etm-0-0-6250]). However, the anti-apoptotic mechanism of Epo in animal models of SE is unclear. In this study, we used pentylenetetrazol (PTZ) to induce epileptic seizures in rats to establish the SE model. The effects of Epo on neuronal apoptosis after epileptic seizures induced by PTZ, and on the expression of mitochondrial-apoptosis-pathway-related regulator Bcl-2 and Bad were observed, as well as whether the PI3K/Akt pathway was an important approach of neuroprotective effect of Epo to reduce apoptosis and promote survival.

Materials and methods
=====================

### Experimental animals

A group of healthy adult rats (all male, 3--4 months) of Sprague-Dawley (SD) strain from Hebei Experimental Animal Center were selected. The range of initial weight was 220±20 g. Attempts were made to minimize the number of animals used. Rats were normally fed with food and water and group-housed in plastic cages on a standard 12/12 h ligh/dark cycle. The temperature was maintained within a normal range.

### Main experimental reagents and equipments

Dimethyl sulphoxide (DMSO), LY294002 and PTZ (Sigma-Aldrich, St. Louis, MO, USA), recombinant human erythropoietin (rHuEpo) (North China Pharmaceutical Group Jintan Co., Ltd., Shijiazhuang, China), mouse monoclonal anti-rat phospho-Thr308-Akt, rat Bcl-2, Bad polyclonal antibodies (cat. nos. sc-377457, sc-56015, sc-8044; all from Santa Cruz Biotechnology, Inc., Dallas, TX, USA), *in situ* apoptosis detection kit (Roche Diagnostics, Indianapolis, IN, USA), 7314F electroencephalograph (Neurofax; Nihon Kohden Corporation, Tokyo, Japan), SR-6N stereotaxic apparatus (Narishige, Tokyo, Japan), microscopes (Olympus Corporation, Tokyo, Japan), pathology image analysis software (Beijing University of Aeronautics and Astronautics Image Center, Beijing, China), RT-PCR reverse transcription and amplification reagents (Promega Corporation, Madison, WI, USA), primers (Sangon Biotech Co., Ltd., Shanghai, China), PCR instrument (Eppendorf, Hamburg, Germany), gel scanning analysis system (Syngene Europe, Cambrige, UK).

### SE model preparation and grouping

A total of 197 rats were used to prepare SE model based on the accepted approach and dosage: at first, PTZ 20 mg/kg was given by intraperitoneal injection. Then 10 mg/kg PTZ was injected each time at the interval of 10 min until generalized epileptic seizures and/or SE occurred. The performance of rats after administration was evaluated according to Racine\' scale. Grade 0, no abnormal performance; grade I, facial muscle twitch and/or rhythmic mastication; grade II, regular nodding or wet dog shakes (WDS); grade III, clonus of a single forelimb; grade IV, clonus of both forelimbs with standing posture; grade V, sudden fall and/or generalized tonic-clonic convulsion. When grade IV or V appeared, it was considered as a generalized seizure, and regarded as SE when the duration of onset was 30 min or more. In order to ensure experiment scale, rats of midway-death or unsuccessful models were removed and randomly supplemented. The final 125 successful models were randomly divided into 5 groups: normal control group \[normal saline (NS)\], model group (PTZ + NS), rHuEpo intervention group (PTZ + rHuEpo), LY294002 intervention group (PTZ + rHuEpo + LY294002) and LY294002 control group (PTZ + rHuEpo + DMSO), with 25 rats in each group.

### Drug administration

Model group: An intraperitoneal injection (i.p.) of 2 ml of 0.9% sodium chloride solution at 30 min after SE was induced with PTZ. rHuEpo intervention group: an intraperitoneal injection of rHuEpo 5,000 U/kg at 30 min after SE was induced with PTZ. LY294002 intervention group (with DMSO as solvent, LY294002 concentration at 10 µg/5 µl): an intraventricular injection of 5 µl of LY294002 at 10 min after SE was induced with PTZ, followed by an intraperitoneal injection of rHuEpo 5,000 U/kg at 30 min after SE. LY294002 control group: an intraventricular injection of 5 µl of DMSO at 10 min after SE was induced with PTZ, followed by an intraperitoneal injection of rHuEpo 5,000 U/kg at 30 min after SE. Normal control group: an intraperitoneal injection of 0.9% sodium chloride solution of the same volume.

### Stereotaxic localization of lateral ventricle and administration in rats

The Rat Brain in Stereotaxic Coordinates was used as the standard to locate the injection site (0.8 mm backward the anterior fontanelle, 1.5 mm aside the sagittal slit and 3.8 mm under the dura mater). First, SE was induced with PTZ. After 10 min, the LY294002 intervention group was injected with 5 µl of LY294002, while the LY294002 control group was injected with 5 µl of DMSO. The needles were not drawn until 5 min after injection, while the behavior of the rat was observed.

### Behavioral observation and electroencephalogram (EEG) of rats

Continuous behavioral observation lasted for 2 h after the drug administration. Whether there was seizure onset, manifestation and duration were recorded in detail.

EEG: Five rats in each group were randomly selected for EEG recording. An intraperitoneal injection of 4% chloral hydrate (35 mg/kg) was given for anaesthesia, and the rat skull was carefully exposed after fixed to the cephalostat. Eight leads were connected by 4 electrodes on the left and right hippocampus and cortex. The position of cortical electrode: 2 mm forward the anterior fontanelle, 2 mm aside to the midline and 2 mm in depth. The position of hippocampal electrode: 3.8 mm backward the anterior fontanelle, 2.4 mm aside to the middle line and 3.8 mm in depth. The electrodes were placed and fixed after drilling, with the reference electrode placed at the tip of the rat\'s nose. EEG machine parameters were set as follows: paper speed of 30 mm/sec, sensitivity of 20 µV/mm, wave filtering of 15 Hz, time constant of 0.1. EEG was recorded after the rat awoke from anesthesia.

Observation of hippocampal histology
------------------------------------

### Specimen preparation

At 24 h after onset of SE, excessive anesthesia was applied. After exposure of the heart, the aorta was intubated from the left ventricle, and the opening of the right atrial appendage made the perfusion fluid flow out smoothly. After connected to the perfusion system, NS and 4% paraformaldehyde were injected successively, each in the volume of 500 ml. Then the brain tissue was quickly taken out after craniotomy and vertically transected at the optic chiasma and mammillary bodies. The middle-segment brain tissue containing hippocampus and intraventricular injection site was fully soaked in the solution of sufficient polyformaldehyde for 24 h at 4°C followed by dehydration and embedding. The tissue was continuously cut into slices all the way to the hippocampal level at the thickness of 5 µm from coronal position. The sections were prepared for TUNEL and immunohistochemical staining.

### Histopathological observation of hippocampus

i\) TUNEL staining by TUNEL kit. After the sections were deparaffinized and rehydrated, the proteinase K (which does not contain deoxyribonuclease) was added for incubation. After full washing with PBS, the conversion agent POD was added, followed by the steps of color rendering, redyeing and covering. All the specimens were processed into 3 sections according to the methods above. In each of the hippocampal sections, 10 non-overlapping fields were selected by random, and the number of cells with dyed and visible nuclei was counted. The average value of 30 counts of each sample was taken as final result, and the average counts of samples in each group were obtained.

ii\) Immunohistochemical staining: the Streptavidin-Perosidase method was employed. After deparaffinized and hydrated, the sections were washed with PBS 3 times, and 3% H~2~O~2~ was used for quenching endogenous peroxidase activity. Normal low-lethal serum was used as a blocking buffer after PBS rinsing again. Mouse monoclonal anti-phospho-Thr308-Akt antibody (diluted 1:200), anti-Bcl-2 antibody (diluted 1:200), anti-Bad antibody (diluted 1:150) were added and placed at 4°C overnight, and biotinylated goat anti-rabbit IgG was added at room temperature after PBS flushing. Incubation, color rendering, redyeing and covering were sequentially carried out. PBS was used to replace Bcl-2 and Bad polyclonal antibodies in the control group. The observation target was the expression of Bcl-2 and Bad in hippocampal tissues. All the specimens were processed into 3 sections according to the method above. In each of the hippocampal sections, 10 non-overlapping fields were selected randomly, and the number of cells with dyed and visible nuclei was counted. The average value of 30 counts of each sample was taken as final result, and the average count of samples in each group was obtained.

### RT-PCR detection

Ten rats were randomly selected from each group and the hippocampus was quickly taken out after death. The total RNA of each rat\'s hippocampus was extracted according to the instruction of TRIzol reagent, and the purity and concentration were measured by ELISA microplate reader. A total of 2 µg of each sample was used for reverse transcription into its complementary DNA, and 1 µg of the complementary DNA was used as substrate for PCR amplification. The primers were customized at Sangon Biotech Co., Ltd. A total of 5 µl of each reverse transcriptase PCR (RT-PCR) amplification product was observed after electrophoresis on 2% agarose gel, and the density of each band was analyzed on the gel image analysis system to obtain semi-quantitative results. The statistical analysis was carried out after 5 repeated average calculations. The relative content of the product was exhibited by the ratio of Bad/β-actin and Bcl-2/β-actin.

### Western blotting

In each group, 10 experimental rats were randomly selected. After rapid sacrifice, the hippocampal tissues were rapidly removed. The total protein was extracted and the concentration was determined (BCA method). After the protein were denatured, electrically transferred and sealed, mouse monoclonal anti-phospho-Thr308-Akt antibody (1:300), anti-Bcl-2 antibody (1:200) and anti-Bad antibody (1:150) were added into 50 µg of protein and placed at 4°C overnight. After TPBS bleaching, the rabbit anti-mouse Igg monoclonal antibody (1:3,000; cat. no. 58802; Cell Signaling Technology, Danvers, MA, USA) was added. After incubation for 1 h, the target was rinsed with TPBS and PBS, respectively. The target strip and the β-actin strip were scanned and the unit density was measured. The ratio of the two was calculated and analyzed statistically, then repeated 5 times to calculate the mean value and carry out final statistical analysis.

### Statistical analysis

All the data collected in the experiment are expressed as the mean ± standard deviation. The data were analyzed by SPSS 21 software (IBM Corp., Armonk, NY, USA). One-way ANOVA with Student-Newman-Keuls post hoc test was used for multiple comparisons among the groups. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Behavioral changes in rats

A total of 197 rats were injected with PTZ. The minimum dose and quantity distribution of convulsion were 30 mg/kg (75), 40 mg/kg (77), and 50 mg/kg (45). The main manifestations of convulsion are rhythmic head retraction and myoclonus. The injection dose of PTZ increased rapidly with the time gradient, rapidly triggering the twitching of the limbs of the rats. The self-regulation ability of the body posture was quickly lost in the stage of generalized tonic-clonic seizures. Severe contraction of the extensors in the anterior and hind limbs of the rats were observed and respiratory depression appeared. Hyperemia of eyeball and blue around the lips were also observed. Within a few minutes, generalized tonic-clonic convulsion occurred with the SE duration of 30 min or more. Approximately 35% rats died during the process, and 3 unsuccessful modeling rats were removed and randomly supplemented. No behavioral changes were found in the normal control group.

### Changes of EEG

The EEG of the model group showed a large number of paroxysmal high amplitude spike waves, sharp waves, sharp slow/spike slow complex waves. The frequency and/or amplitude of epileptic seizures in the rHuEpo intervention the LY294002 intervention and the LY294002 control groups were significantly lower than those in the model group, which indicated the epileptic discharge was significantly inhibited. Compared with the LY294002 intervention group, epileptic discharges in the rHuEpo intervention group and the LY294002 control group decreased significantly.

### TUNEL staining results ([Table I](#tI-etm-0-0-6250){ref-type="table"})

Apoptotic cells are TUNEL-positive cells featured with brown yellow nuclei under the light microscope. There was significant difference for TUNEL-positive cells (F4, 45=19.19, P\<0.05) among the five groups. In the normal control group, there were few apoptotic cells in brain tissue slices, while in the other groups, apoptotic cells were distributed in hippocampal areas to a different degree. The number of apoptotic cells in the normal control group was significantly less than that in the other 4 groups (P\<0.05). The frequency of apoptotic cells in the slices of the model group was significantly increased, with the nuclei fixed in a circular or irregular shape. Under high power microscope, chromatin staining, aggregation, fragmentation and other phenomena can be observed, which is consistent with the morphological characteristics of apoptotic cells. The number of apoptotic cells in the rHuEpo intervention, the LY294002 intervention and the LY294002 control groups was significantly less than that in the model group (P\<0.05). The number of apoptotic cells in the rHuEpo intervention group and the LY294002 control group was significantly less than that in the LY294002 intervention group (P\<0.05). The number of apoptotic cells in the LY294002 control group was more than that in the rHuEpo intervention group, but there was no statistical difference (P\>0.05).

### Immunohistochemical staining results

The expression of p-Akt, Bcl-2 and Bad in hippocampus ([Tables I](#tI-etm-0-0-6250){ref-type="table"}--[III](#tIII-etm-0-0-6250){ref-type="table"}; [Figs. 1](#f1-etm-0-0-6250){ref-type="fig"} and [2](#f2-etm-0-0-6250){ref-type="fig"}).

Brown yellow is positive for staining, mainly located in cytoplasm, with a small amount in nuclei and membranes. There was significant difference for the number of p-Akt-IR cells (F4, 45=28.77, P\<0.05), Bcl-2-IR cells (F4, 45=19.27, P\<0.05) and Bad-IR cells (F4, 45=21.00, P\<0.05) among the five groups. In the cytoplasm of the normal control group, there were occasionally scattered brown yellow particles in the cytoplasm. Compared with the normal control group, the number of p-Akt-, Bcl-2- and Bad-positive cells in the other 4 groups showed a significant increase, showing statistical difference (P\<0.05). The number of p-Akt- and Bcl-2-positive cells in the rHuEpo intervention group, the LY294002 intervention group and the LY294002 control group was significantly more than that in the model group, while the number of Bad-positive cells was significantly less than that in the model group, showing statistical difference (P\<0.05). Compared with the LY294002 intervention group, the number of p-Akt- and Bcl-2-positive cells in the rHuEpo intervention group and the LY294002 control group was more, but the number of Bad-positive cells was less, showing statistical difference (P\<0.05). Compared with the LY294002 control group, the number of p-Akt and Bcl-2-positive cells in the rHuEpo intervention group was more, but the number of Bad-positive cells was less, showing no statistical difference (P\>0.05).

### RT-PCR to determine the expression of Bcl-2 mRNA and Bad mRNA ([Tables II](#tII-etm-0-0-6250){ref-type="table"} and [III](#tIII-etm-0-0-6250){ref-type="table"}; [Figs. 3](#f3-etm-0-0-6250){ref-type="fig"}--[5](#f5-etm-0-0-6250){ref-type="fig"})

There was significant difference for Bcl-2 mRNA (F4, 45=27.95, P\<0.05) and Bad mRNA (F4, 45=13.12, P\<0.05) among the five groups. There were weak expressions of Bcl-2 mRNA and Bad mRNA in the control group. Compared with the control group, the expression of Bcl-2 mRNA and Bad mRNA in the model, the rHuEpo intervention, the LY294002 intervention and the LY294002 control groups all increased significantly (P\<0.05). The expression of Bad mRNA in the model group was significantly higher than that in the rHuEpo intervention, the LY294002 intervention and the LY294002 control groups, and the expression of Bcl-2 mRNA was significantly decreased (P\<0.05). Compared with the LY294002 intervention group, the expression of Bad mRNA in the rHuEpo intervention group and LY294002 control group decreased significantly, and the expression of Bcl-2 mRNA increased significantly (P\<0.05). Compared with the LY294002 control group, the expression of Bad mRNA in the rHuEpo intervention group decreased and the expression of Bcl-2 mRNA increased, showing no statistical difference (P\>0.05).

### Western blotting to determine the expression of Akt, p-Akt, Bcl-2 and Bad ([Tables I](#tI-etm-0-0-6250){ref-type="table"}--[III](#tIII-etm-0-0-6250){ref-type="table"}; [Figs. 4](#f4-etm-0-0-6250){ref-type="fig"}--[6](#f6-etm-0-0-6250){ref-type="fig"})

The expression of Akt and p-Akt, Bcl-2 and Bad protein in the hippocampus of rats was detected by western blotting. There was significant difference for p-Akt (F4, 45=15.70, P\<0.01), Bcl-2 (F4, 45=18.07, P\<0.05) and Bad (F4, 45=22.07, P\<0.05) among the five groups, while no significant difference was detected for total AKT between each experimental groups (F4, 45=0.02, P\>0.05). The results showed that compared with the model group, rHuEpo intervention group, LY294002 intervention group and LY294002 control group, the expression of p-Akt, Bcl-2 and Bad in the control group increased significantly (P\<0.05). Compared with the rHuEpo intervention group, the LY294002 intervention group and the LY294002 control group, the expression of p-Akt and Bcl-2 in the PTZ group was obviously decreased, and the expression of Bad was significantly increased (P\<0.05). Compared with the LY294002 intervention group, the expression of p-Akt and Bcl-2 in the rHuEpo intervention group and the LY294002 control group increased significantly, and the expression of Bad protein decreased significantly, showing statistical difference (P\<0.05). Although compared with rHuEpo intervention group, the expression of p-Akt and Bcl-2 in the LY294002 control group decreased, and the expression of Bad increased, there was no statistical difference (P\>0.05). The intervention of rHuEpo, LY294002 and DMSO had no significant effect on the expression of Akt, and there was no statistical difference in the level of expression among groups (P\>0.05).

Discussion
==========

The persistent state of epilepsy is an emergency of the neurology department. If it is not treated in time, secondary to brain edema, brain hernia, respiratory and circulation system failure can cause persistent brain damage and cognitive impairment, and the mortality rate is \~10-12% ([@b8-etm-0-0-6250]). In this study, it was used to improve the concentration of extracellular K^+^, depolarize the cell membrane and improve the excitatory PTZ as epileptogenic agent. There was no other neurotoxicity in PTZ itself. So it is a scientific choice to use PTZ as an epileptogenic agent to study neuron apoptosis damage attributed to SE. EEG and Racine grading were used to test the success of the SE model. Previous study shows that the damage of neurons after SE seizures is a mixed state of apoptosis, necrosis and coexistence of both, in which apoptosis is a very important damage form ([@b9-etm-0-0-6250]), but the mechanism of its occurrence is not clear. Some studies have observed that apoptotic neurons and apoptotic bodies appear in different degrees in the hippocampus of epileptic rats, while the activity of apoptosis-related factors enhanced, and the apoptotic cells with positive TUNEL staining appear in large numbers. In this study, the changes of apoptotic cells were observed by TUNEL staining in the PTZ kindled SE model rats. The results showed that a mass of epileptiform discharges were found in the EEG of the model group, and portion of the hippocampal neurons were necrosis and apoptosis, and the number of apoptotic cells increased more than that in the normal control group.

Mitochondria-dependent pathways play an important role in three of the main apoptotic-dependent pathways including mitochondria, death receptors and endoplasmic reticulum. The main sites and effective sites of the Bcl-2 family proteins are all on the mitochondrial membrane. The Bcl-2 family is the key to the integration of the signal to the cell mitochondria, which is called 'the doorman of apoptosis'. The members of Bcl-2 can form dipolymers, including homologous dipolymers or hetero-dipolymers, and these dipolymers play a vital role in the dynamic balance of cell survival and death, and then determine the fate of cells. The role of pro-apoptotic protein Bad is closely related to Bcl-2 and Bcl-xL. Through the concentration-dependent form, Bad replaces the apoptotic protein Bax in the Bcl-2/Bax, Bcl-xL/Bax dipolymer, which promotes the formation of a large amount of homologous dipolymers. When the homologous dipolymers content \>80%, induced by apoptotic stimulation signal, programmed-death/apoptosis appears in the cell. The ratio of Bax homologous dipolymers and hetero-dipolymers determine the survival of neurons, and Bad takes effect on promoting apoptosis by regulating this ratio. When the content of Bcl-xL/Bax and Bcl-2/Bax dipolymers in the cell is ≥50%, the cells can resist apoptosis. Therefore, Bcl-2 and Bad are very important factors in Bcl-2 family. The changes of Bcl-2 and Bad were observed by immunohistochemistry, reverse transcription-PCR and western blotting in our study. The experimental results showed that the expressions of Bcl-2 and Bad immunoreactive cells, Bcl-2 mRNA, Bad mRNA and Bcl-2, Bad protein in the model group were significantly upregulated than the normal control group, which indicating PTZ activated Bad and Bcl-2 protein and mRNA increased significantly in the hippocampus neurons. The study of Henshall *et al* ([@b10-etm-0-0-6250]) and Meller *et al* ([@b11-etm-0-0-6250]) also found that Bcl-2 and Bad proteins may be activated and involved in neuronal apoptosis, which is consistent with our experimental results.

The in-depth study of pathophysiology of SE and the development of new effective therapeutic drugs are still difficult but are hot topics in world medical community now and even in the future. Cortex, hippocampus, astrocytes and brain capillary endothelial cells in brain tissue contain Epo receptors and can also produce endogenous Epo ([@b12-etm-0-0-6250]). Endogenous Epo needs full synthesis of protein and RNA transcription in neurons. Endogenous Epo production is inadequate in acute brain injury. The supply of exogenous Epo can reduce neuron damage. In this experiment, rHuEpo was used as a neuroprotective agent for intraperitoneal injection in the half hour after SE. The results showed that the intervention of rHuEpo could significantly reduce the occurrence of epileptic discharge, upregulate the expression of Bcl-2 protein and mRNA in hippocampal neurons, downregulate the expression of apoptotic protein Bad and mRNA, suggesting that rHuEpo can regulate the expression level of these mitochondria apoptotic pathway related factors then reduce the necrosis and apoptosis of hippocampal neurons and play a neuroprotective role. Based on the above research, how rHuEpo regulates Bcl-2 and Bad, and then achieves neuroprotective effect against apoptosis becomes our research direction.

The PI3K/Akt signal transduction pathway is a classic signal transduction pathway that has biological effect. It plays a multiple role in regulating cell growth, proliferation, differentiation and survival. PI3K/Akt signaling pathway is widespread in the nervous system, which can promote the survival of neurons through regulation and management of apoptosis and autophagy. Li *et al* ([@b13-etm-0-0-6250]) found that the improvement of ginseng protein in Alzheimer\'s disease was also mediated by activation of PI3K/Akt signaling pathway. Uzüm *et al* ([@b14-etm-0-0-6250]) found that Epo given through the abdominal cavity 24 h before the seizure would reduce the intensity of tonic clonic seizure and prolong the latent period of epileptic seizure. The activation of Akt induced by Epo is the key to exert its antiapoptotic effect. Akt is a direct downstream substrate of PI3K. The expression of p-Akt can infer the activation of PI3K/Akt pathway. In our study, we observed the changes of p-Akt by immunohistochemistry and western blotting to study the activation of PI3K/Akt pathway in SE. The results showed that rHuEpo increased the level of p-Akt in hippocampal neurons significantly, which suggests the neuroprotective effect of rHuEpo was closely related to the activation of PI3K/Akt pathway.

The role of PI3K/Akt pathway in promoting cell survival also have a series of important biological effects by regulating its downstream apoptosis-related proteins. Among them, the regulation of antiapoptotic protein Bcl-2 and proapoptotic protein Bad in Bcl-2 family plays a significant role in nervous system diseases. After ischemic/anoxic stimulation, PI3K can be activated to phosphorylate Akt. P-Akt phosphorylates Bad in Ser136 and combines with chaperone 14--3-3 to form a complex. Bad is dissociated from heterogeneous dipolymer, which indirectly increases the expression of Bcl-2 and weakens the damage of apoptosis. Fu *et al* ([@b15-etm-0-0-6250]) found that PI3K/Akt/Bad signaling pathway played a role in apoptosis of PC12 cells induced by taxol. The expression level of Bcl-2 is regulated by p-Akt, thus exerting neuroprotective effect ([@b16-etm-0-0-6250]). The results of knockout Akt mice showed that the level of p-Akt decreased, the expression of Bcl-2 protein in cytoplasm was reduced, and the damage of neurons was aggravated. The results of Miao *et al* ([@b17-etm-0-0-6250]) showed that the level of Bcl-2 expression was upregulated and the occurrence of apoptosis decreased, which might be achieved by enhancing PI3K/AKT signal transduction. Kong *et al* ([@b18-etm-0-0-6250]) found that the use of PI3K inhibitor LY294002 could prevent the protective effect due to increased p-Akt level. Xiao *et al* ([@b19-etm-0-0-6250]) studies showed that the expression of interleukin 1β in the induced neurons could upregulate the expression of p-Akt, and the length of the neuron dendrites could rapidly grow, and the expression of p-Akt was downregulated after the pretreatment of LY294002. In this experiment, we also carried out a more in-depth study to further observe whether rHuEpo regulates the mitochondrial apoptosis pathway related regulatory factors Bcl-2 and Bad via the PI3K/Akt pathway in the PTZ induced SE rat model, and offers neuroprotection. We used the PI3K inhibitor LY294002 to block it. The results showed that the protective effect of rHuEpo was obviously weakened when LY294002 was conducted before rHuEpo intervention. There was an increase in the occurrence of epileptic discharge in the LY294002 group and the apoptosis of the hippocampal neurons compared with that in the rHuEpo group, and the results of the immunodeficiency histochemistry and western blotting showed a decreased number of p-Akt- and Bcl-2-positive cells, and the expression of Bcl-2 mRNA and protein were also lower. The number of Bad-positive cells and the expression of Bad mRNA and protein were upregulated. It is further suggested that rHuEpo activates the important survival passageway PI3K/Akt pathway, which is related to improving the activity of Akt, and regulates the regulatory factors of Bcl-2 and Bad of mitochondrial apoptosis pathway through the PI3K/Akt signal transduction pathway to exert neuroprotective effect on antiapoptosis.

There are still some limitations in this study: the observation of large sample quantities without multi time-points. There are cross series between the signal paths and the complexities, and the PI3K/Akt path is not the only signal path of the Epo. How it works with the other channels to carry out 'cross talk' of neuroprotection is not clear. Thus more in-depth studies are required.

In conclusion, Epo directly or indirectly regulates the regulatory factors of Bcl-2 and Bad of mitochondrial apoptosis pathway through PI3K/Akt signaling pathway, participates in the different stages of apoptosis, and then exerts neuroprotective effect on antiapoptosis and pro-survival. As a neuroprotective agent, Epo is widely used in the basic research of all kinds of nervous system diseases, such as closed brain injury, neonatal hypoxic encephalopathy and Alzheimer\'s disease. But the safe dose and treatment time of neuroprotection of Epo are different. The safety, dose dependence and time selectivity of Epo have attracted much attention. The study of Epo and formylated Epo is also being carried out to provide an important laboratory basis for the search for effective and feasible neuroprotective agents for the treatment of epilepsy.
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![The expression of Bcl-2-positive cells in rat hippocampus (SP, −400). (A) Control group; (B) model group; (C) rHuEpo treated group; (D) LY294002 treated group; (E) LY294002 control group.](etm-16-02-0847-g00){#f1-etm-0-0-6250}

![The expression of Bad-positive cells in rat hippocampus (SP, −400). (A) Control group; (B) model group; (C) rHuEpo treated group; (D) LY294002 treated group; (E) LY294002 control group.](etm-16-02-0847-g01){#f2-etm-0-0-6250}

![The expression of Bcl-2 mRNA in rat hippocampus of each group. Lane 1, control group; lane 2, model group; lane 3, rHuEpo treated group; lane 4, LY294002 treated group; lane 5, LY294002 control group. Model group vs. rHuEpo treated group (\*p\<0.05); rHuEpo treated group vs. LY294002 treated group (^\#^p\<0.05). PTZ, pentylenetetrazol; rHuEpo, recombinant human erythropoietin; DMSO, dimethyl sulphoxide.](etm-16-02-0847-g02){#f3-etm-0-0-6250}

![The expression of Bcl-2 protein in rat hippocampus of each group. Lane 1, control group; lane 2, model group; lane 3, rHuEpo treated group; lane 4, LY294002 treated group; lane 5, LY294002 control group. Model group vs. rHuEpo treated group (\*p\<0.05); rHuEpo treated group vs. LY294002 treated group (^\#^p\<0.05). PTZ, pentylenetetrazol; rHuEpo, recombinant human erythropoietin; DMSO, dimethyl sulphoxide.](etm-16-02-0847-g03){#f4-etm-0-0-6250}

![The expression of Bad mRNA in rat hippocampusof each group. Lane 1, control group; lane 2, model group; lane 3, rHuEpo treated group; lane 4, LY294002 treated group; lane 5, LY294002 control group. Model group vs. rHuEpo treated group (\*p\<0.05); rHuEpo treated group vs. LY294002 treated group (^\#^p\<0.05). PTZ, pentylenetetrazol; rHuEpo, recombinant human erythropoietin; DMSO, dimethyl sulphoxide.](etm-16-02-0847-g04){#f5-etm-0-0-6250}

![The expression of Bad protein in rat hippocampus of each group. Lane 1, control group; lane 2, model group; lane 3, rHuEpo treated group; lane 4, LY294002 treated group; lane 5, LY294002 control group. Model group vs. rHuEpo treated group (\*p\<0.05); rHuEpo treated group vs. LY294002 treated group (^\#^p\<0.05). PTZ, pentylenetetrazol; rHuEpo, recombinant human erythropoietin; DMSO, dimethyl sulphoxide.](etm-16-02-0847-g05){#f6-etm-0-0-6250}

###### 

The count of apoptotic cells, p-Akt-positive cells and p-Akt protein of hippocampus area in each group (mean ± standard deviation, n=10).

  Groups                   Apoptotic cells                                                                                          p-Akt-positive cells                                                                                     p-Akt
  ------------------------ -------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------
  Control group            7.23±1.05                                                                                                21.41±1.20                                                                                               0.398±0.064
  Model group              26.72±3.53^[a](#tfn1-etm-0-0-6250){ref-type="table-fn"}^                                                 26.57±2.46^[a](#tfn1-etm-0-0-6250){ref-type="table-fn"}^                                                 0.528±0.044^[a](#tfn1-etm-0-0-6250){ref-type="table-fn"}^
  rHuEpo treated group     16.59±1.12^[a](#tfn1-etm-0-0-6250){ref-type="table-fn"}--[c](#tfn3-etm-0-0-6250){ref-type="table-fn"}^   54.81±5.08^[a](#tfn1-etm-0-0-6250){ref-type="table-fn"}--[c](#tfn3-etm-0-0-6250){ref-type="table-fn"}^     0.759±0.027^[a](#tfn1-etm-0-0-6250){ref-type="table-fn"}--[c](#tfn3-etm-0-0-6250){ref-type="table-fn"}^
  LY294002 treated group   21.08±2.67^[a](#tfn1-etm-0-0-6250){ref-type="table-fn"},[b](#tfn2-etm-0-0-6250){ref-type="table-fn"}^    33.07±4.87^[a](#tfn1-etm-0-0-6250){ref-type="table-fn"},[b](#tfn2-etm-0-0-6250){ref-type="table-fn"}^      0.64±0.012^[a](#tfn1-etm-0-0-6250){ref-type="table-fn"},[b](#tfn2-etm-0-0-6250){ref-type="table-fn"}^
  LY294002 control group   17.47±1.86^[a](#tfn1-etm-0-0-6250){ref-type="table-fn"}--[c](#tfn3-etm-0-0-6250){ref-type="table-fn"}^   52.35±4.63^[a](#tfn1-etm-0-0-6250){ref-type="table-fn"}--[c](#tfn3-etm-0-0-6250){ref-type="table-fn"}^   0.756±0.027^[a](#tfn1-etm-0-0-6250){ref-type="table-fn"}--[c](#tfn3-etm-0-0-6250){ref-type="table-fn"}^
  F-value                  19.19                                                                                                    28.77                                                                                                    15.70
  P-value                  \<0.05                                                                                                   \<0.05                                                                                                   \<0.01

P\<0.05, control group vs. model, rHuEpo treated, LY294002 treated, LY294002 control groups

P\<0.05, model group vs. rHuEpo treated, LY294002 treated, LY294002 control groups

P\<0.05, LY294002 treated group vs. rHuEpo treated, LY294002 control groups. No significant difference was found between rHuEpo treated group and LY294002 control group. rHuEpo, recombinant human erythropoietin.

###### 

The count of Bcl-2 positive cells, Bcl-2 mRNA, Bcl-2 protein of rats hippocampus area in each group (mean ± standard deviation, n=10).

  Groups                   Bcl-2 positive cells                                                                                       Bcl-2 mRNA                                                                                                Bcl-2
  ------------------------ ---------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------
  Control group            23.197±2.726                                                                                               0.440±0.076                                                                                               0.349±0.049
  Model group              29.606±2.143^[a](#tfn4-etm-0-0-6250){ref-type="table-fn"}^                                                 0.605±0.051^[a](#tfn4-etm-0-0-6250){ref-type="table-fn"}^                                                 0.508±0.044^[a](#tfn4-etm-0-0-6250){ref-type="table-fn"}^
  rHuEpo treated group     42.639±1.829^[a](#tfn4-etm-0-0-6250){ref-type="table-fn"}--[c](#tfn6-etm-0-0-6250){ref-type="table-fn"}^   0.984±0.019^[a](#tfn4-etm-0-0-6250){ref-type="table-fn"}--[c](#tfn6-etm-0-0-6250){ref-type="table-fn"}^   0.791±0.045^[a](#tfn4-etm-0-0-6250){ref-type="table-fn"}--[c](#tfn6-etm-0-0-6250){ref-type="table-fn"}^
  LY294002 treated group   35.415±2.011^[a](#tfn4-etm-0-0-6250){ref-type="table-fn"},[b](#tfn5-etm-0-0-6250){ref-type="table-fn"}^    0.843±0.034^[a](#tfn4-etm-0-0-6250){ref-type="table-fn"},[b](#tfn5-etm-0-0-6250){ref-type="table-fn"}^    0.636±0.021^[a](#tfn4-etm-0-0-6250){ref-type="table-fn"},[b](#tfn5-etm-0-0-6250){ref-type="table-fn"}^
  LY294002 control group   41.060±0.476^[a](#tfn4-etm-0-0-6250){ref-type="table-fn"}--[c](#tfn6-etm-0-0-6250){ref-type="table-fn"}^   0.981±0.021^[a](#tfn4-etm-0-0-6250){ref-type="table-fn"}--[c](#tfn6-etm-0-0-6250){ref-type="table-fn"}^   0.762±0.050^[a](#tfn4-etm-0-0-6250){ref-type="table-fn"}--[c](#tfn6-etm-0-0-6250){ref-type="table-fn"}^
  F-value                  19.27                                                                                                      27.95                                                                                                     18.07
  P-value                  \<0.05                                                                                                     \<0.05                                                                                                    \<0.05

P\<0.05, control group vs. model group, rHuEpo treated, LY294002 treated, LY294002 control groups

P\<0.05, model group vs. rHuEpo treated, LY294002 treated, LY294002 control groups

P\<0.05, LY294002 treated group vs. rHuEpo treated, LY294002 control groups. No significant difference was found between rHuEpo treated group and LY294002 control group. rHuEpo, recombinant human erythropoietin.

###### 

The count of Bad positive cells, Bad mRNA, Bad protein of rats hippocampus area in each group (mean ± standard deviation, n=10).

  Groups                   Bad-positive cells                                                                                         Bad mRNA                                                                                                  Bad
  ------------------------ ---------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------
  Control group            16.931±1.158                                                                                               0.350±0.041                                                                                               0.291±0.033
  Model group              43.804±4.386^[a](#tfn7-etm-0-0-6250){ref-type="table-fn"}^                                                 0.728±0.076^[a](#tfn7-etm-0-0-6250){ref-type="table-fn"}^                                                 0.668±0.045^[a](#tfn7-etm-0-0-6250){ref-type="table-fn"}^
  rHuEpo treated group     24.060±0.807^[a](#tfn7-etm-0-0-6250){ref-type="table-fn"}--[c](#tfn9-etm-0-0-6250){ref-type="table-fn"}^   0.493±0.013^[a](#tfn7-etm-0-0-6250){ref-type="table-fn"}--[c](#tfn9-etm-0-0-6250){ref-type="table-fn"}^   0.408±0.017^[a](#tfn7-etm-0-0-6250){ref-type="table-fn"}--[c](#tfn9-etm-0-0-6250){ref-type="table-fn"}^
  LY294002 treated group   35.424±2.290^[a](#tfn7-etm-0-0-6250){ref-type="table-fn"},[b](#tfn8-etm-0-0-6250){ref-type="table-fn"}^    0.608±0.014^[a](#tfn7-etm-0-0-6250){ref-type="table-fn"},[b](#tfn8-etm-0-0-6250){ref-type="table-fn"}^    0.542±0.021^[a](#tfn7-etm-0-0-6250){ref-type="table-fn"},[b](#tfn8-etm-0-0-6250){ref-type="table-fn"}^
  LY294002 control group   24.308±0.677^[a](#tfn7-etm-0-0-6250){ref-type="table-fn"}--[c](#tfn9-etm-0-0-6250){ref-type="table-fn"}^   0.495±0.013^[a](#tfn7-etm-0-0-6250){ref-type="table-fn"}--[c](#tfn9-etm-0-0-6250){ref-type="table-fn"}^   0.454±0.026^[a](#tfn7-etm-0-0-6250){ref-type="table-fn"}--[c](#tfn9-etm-0-0-6250){ref-type="table-fn"}^
  F-value                  21.00                                                                                                      13.12                                                                                                     22.07
  P-value                  \<0.05                                                                                                     \<0.05                                                                                                    \<0.05

P\<0.05, control group vs. model, rHuEpo treated, LY294002 treated, LY294002 control groups

P\<0.05, model group vs. rHuEpo treated, LY294002 treated, LY294002 control groups

P\<0.05, LY294002 treated group vs. rHuEpo treated, LY294002 control groups. No significant difference was found between rHuEpo treated group and LY294002 control group. rHuEpo, recombinant human erythropoietin.

[^1]: Contributed equally
